Prevention of Metastasis by Suppression of Stemness Genes Using a Combination of microRNAs

Nevskaya, Kseniya V.; Pershina, Alexandra G.; Hmelevskaya, Ekaterina S.; Efimova, Lina V.; Ibragimova, Marina K.; Dolgasheva, Darya S.; Tsydenova, Irina A.; Ufandeev, Alexander A.; Buyko, Evgeny E.; Perina, Ekaterina A.; Gaptulbarova, Ksenia A.; Kravtsova, Ekaterina A.; Krivoshchekov, Sergei V.; Ivanov, Vladimir V.; Guriev, Artem M.; Udut, Elena V.; Litviakov, Nikolai V.

doi:10.1021/acs.jmedchem.3c02199

Cited by 2 publications

(1 citation statement)

References 53 publications

(57 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Data show that the system effectively inhibited the ability of cells to form mammospheres in vitro and prevented lung metastasis in a C57L/6 mouse model (Fig. 6) [145].…”

Section: Lnps For Mirna Deliverymentioning

confidence: 89%

Lipid nanoparticles-based RNA therapies for breast cancer treatment

Serpico,

Zhu,

Maia

et al. 2024

Drug Deliv. and Transl. Res.

View full text Add to dashboard Cite

Breast cancer (BC) prevails as a major burden on global healthcare, being the most prevalent form of cancer among women. BC is a complex and heterogeneous disease, and current therapies, such as chemotherapy and radiotherapy, frequently fall short in providing effective solutions. These treatments fail to mitigate the risk of cancer recurrence and cause severe side effects that, in turn, compromise therapeutic responses in patients. Over the last decade, several strategies have been proposed to overcome these limitations. Among them, RNA-based technologies have demonstrated their potential across various clinical applications, notably in cancer therapy. However, RNA therapies are still limited by a series of critical issues like off-target effect and poor stability in circulation. Thus, novel approaches have been investigated to improve the targeting and bioavailability of RNA-based formulations to achieve an appropriate therapeutic outcome. Lipid nanoparticles (LNPs) have been largely proven to be an advantageous carrier for nucleic acids and RNA. This perspective explores the most recent advances on RNA-based technology with an emphasis on LNPs’ utilization as effective nanocarriers in BC therapy and most recent progresses in their clinical applications. Graphical Abstract

show abstract

“…Data show that the system effectively inhibited the ability of cells to form mammospheres in vitro and prevented lung metastasis in a C57L/6 mouse model (Fig. 6) [145].…”

Section: Lnps For Mirna Deliverymentioning

confidence: 89%